BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 by $0.00. The company also reported revenue of $667,500,000, missing estimates of $686,088,455 by $-18,588,455.
You can see Quiver Quantitative's $BIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIO-RAD LABORATORIES Hedge Fund Activity
We have seen 188 institutional investors add shares of BIO-RAD LABORATORIES stock to their portfolio, and 260 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WEALTHFRONT ADVISERS LLC added 1,043,153 shares (+inf%) to their portfolio in Q4 2024, for an estimated $342,686,192
- VAN ECK ASSOCIATES CORP removed 580,281 shares (-44.5%) from their portfolio in Q4 2024, for an estimated $190,628,111
- MILLENNIUM MANAGEMENT LLC added 575,643 shares (+7057.0%) to their portfolio in Q3 2024, for an estimated $192,598,634
- BANK OF AMERICA CORP /DE/ removed 388,853 shares (-88.0%) from their portfolio in Q3 2024, for an estimated $130,102,436
- NINETY ONE UK LTD removed 387,310 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $129,586,179
- ARIEL INVESTMENTS, LLC added 274,508 shares (+263.5%) to their portfolio in Q3 2024, for an estimated $91,844,886
- POINT72 ASSET MANAGEMENT, L.P. added 250,108 shares (+inf%) to their portfolio in Q3 2024, for an estimated $83,681,134
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO-RAD LABORATORIES Government Contracts
We have seen $5,260,568 of award payments to $BIO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- DIAGNOSTIC TESTING: $717,635
- CONSUMABLES: $584,318
- EVOLIS ANALYZER LEASE AND SERVICE: $349,878
- REAGENTS USED IN BIO-RAD LAB, CHEMISTRY SECTION FOR THE PATHOLOGY DEPARTMENT.: $275,585
- CONSUMABLES: $259,470
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
